Blog→HHS Peptide Compounding Policy: What Med Spas and Wellness Clinics Need to Change (2026)

HHS Peptide Compounding Policy: What Med Spas and Wellness Clinics Need to Change (2026)

HHS's interim policy on compounding BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c: the ten conditions, what it doesn't allow, and what clinics should change.

HHS Peptide Compounding Policy: What Med Spas and Wellness Clinics Need to Change (2026)

Published

Nov 17, 2026

Category

Healthcare Management

Share This

HHS's new peptide compounding policy lets 503A pharmacies and physicians compound six peptides (BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c) without federal enforcement action, but only in specific forms and routes, with a patient-specific prescription, and only while ten conditions are met. It is enforcement discretion, not FDA approval, and HHS published it as a draft interim policy that it can revisit at any time. For a med spa, wellness or longevity clinic, it reopens peptide programs that were on hold, but most of the work it creates sits in your pharmacy choice, your prescribing workflow, your chart and your marketing.

For medical directors, prescribing providers and owners of med spas, wellness and longevity clinics. Updated November 17, 2026 · Prepared by Prospyr. Prospyr makes practice software, not compounded drugs, and does not sell or recommend any peptide. Every rule below links to the Federal Register notice, the HHS policy or a law firm summary of it. This is not legal or clinical advice; confirm your plans with a healthcare attorney and your state medical and pharmacy boards.

What HHS announced

HHS published a notice of availability for its "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" in the Federal Register on October 30, 2026 (91 FR 68526). In it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with the listed peptides while FDA builds the 503A bulks list through rulemaking. The notice calls the document a draft and says HHS may revisit it, in whole or in part, if a safety signal or product quality issue arises.

The policy covers six peptides, each in one salt form and only by the routes listed:

Peptide Form Routes covered
BPC-157 Acetate Subcutaneous, intramuscular, oral, topical
TB-500 Acetate Subcutaneous or intramuscular injection
Epitalon Acetate Subcutaneous or intramuscular injection, dispensed in intermittent courses
MOTS-c Acetate Subcutaneous or intramuscular injection
KPV Acetate Topical, oral
Semax Free base Intranasal

Source: HHS policy, appendices, as summarized by Venable LLP.

A peptide on this list in a different form or by a different route, such as injectable KPV or an oral Semax, is outside the policy.

What the policy does not do

  • It does not make these peptides FDA-approved. The Federal Register notice states that compounded drugs are not FDA-approved and that FDA does not review their safety, effectiveness or quality before they're marketed.
  • It does not add them to the 503A bulks list. FDA's future rulemaking "may propose adding some or all of these peptides," per the notice. Until a final rule addresses each peptide, the policy is the only cover.
  • It is not permanent. Venable notes there is no set expiration date: discretion lasts until each peptide is addressed in a final rule, unless HHS pulls it sooner.
  • It does not cover 503B outsourcing facilities. It applies to 503A compounding, per Venable. If you buy office stock from a 503B outsourcing facility, this policy doesn't change what that facility can make.
  • It does not override state law. State boards of pharmacy and medicine, and state attorneys general, can still apply their own rules, and the American Med Spa Association stresses that it is not a blanket authorization to prescribe, dispense or administer these peptides.

The ten conditions, and who carries each one

According to Venable's summary of the HHS policy, enforcement discretion applies only when all ten conditions are met. Most fall on the compounder, but each one is something your practice should confirm before it prescribes.

Condition (paraphrased) Who carries it What your practice should do
1. The peptide is on the HHS list Pharmacy and prescriber Prescribe only the six listed peptides
2. The substance matches the listed identity and is used only by a listed route Pharmacy and prescriber Write the salt form and route on every order
3. The bulk substance comes from an FDA-registered facility with a valid certificate of analysis Pharmacy Ask the pharmacy for its certificate of analysis
4. The original manufacturer is FDA-registered and follows current good manufacturing practice Pharmacy Ask who manufactures the bulk peptide and where
5. Compounded products, serious adverse events and quality problems are reported to FDA's MedWatch and to the states involved Pharmacy Agree how you'll pass adverse events to the pharmacy
6. The label says "This is a compounded drug product. Not for resale." Pharmacy Check the label on the first fill
7. One active ingredient per product Pharmacy and prescriber Don't order peptide blends or stacks in one vial
8. Oral forms have documented oral bioavailability in humans Pharmacy For oral BPC-157 or KPV, ask for that documentation
9. The only delivery device included is an FDA-cleared syringe Pharmacy Don't dispense pens or devices the pharmacy didn't supply under the policy
10. All other federal requirements are met, including a patient-specific prescription Pharmacy and prescriber Prescribe for an identified patient after an evaluation

Two conditions change what many peptide programs have been doing. Condition 7 rules out the multi-peptide blends some clinics have sold as a single product. Condition 10 keeps section 503A's requirement that the drug be compounded for an identified patient, so a 503A pharmacy can't supply these peptides as general office stock under this policy.

Reading about the problem? See how Prospyr solves it in one platform.

Book a Demo

Questions to ask your compounding pharmacy

Before you restart or launch a peptide service, get written answers to these:

  1. Which of the six peptides do you compound, in which salt forms and routes?
  2. Can you show the certificate of analysis for the bulk peptide, including the original manufacturer's FDA registration and address?
  3. Does your certificate say the substance is intended for human drug compounding, and do you test injectables for endotoxin and bioburden?
  4. How do you report adverse events and quality problems to MedWatch, and how should our providers report to you?
  5. What does your label say, and does it include instructions for patients on reporting side effects?
  6. Are you licensed to ship to patients in our state, and in every state where our patients live?
  7. What will you do if HHS withdraws the policy for a peptide we're prescribing?

If a pharmacy offers blends, "research use only" products, or office stock of these peptides from a 503A license, treat that as a sign it isn't working within the policy.

What changes inside your practice

Prescribing

Every peptide order should name the patient, the peptide, its salt form, the route, the strength and the pharmacy. The prescriber who signs it must be allowed to prescribe under your state's rules, which still decide who can evaluate the patient, who can prescribe, and what a nurse practitioner, physician assistant or registered nurse can do under delegation. Sending orders electronically from the chart makes the patient-specific record automatic; our guide to e-prescribing for med spas covers what to check.

Charting

Your chart should show why this patient is getting this peptide, what the evaluation found, the exact product and route prescribed, and the plan for follow-up. For Epitalon, which the policy limits to intermittent courses, chart the start and end of each course.

Update consent forms so the patient reads, in plain language, that the product is a compounded drug, that it is not FDA-approved, that FDA has not reviewed it for safety or effectiveness, and that federal policy covering it is temporary. Keep the signed consent in the chart.

Adverse events

The pharmacy has to report serious adverse events and quality problems to MedWatch. Make sure your team knows to tell the pharmacy when a patient reports a reaction, and record the report in the chart. Providers can also report directly to FDA MedWatch.

Marketing

Don't describe these peptides as "FDA-approved," "legalized" or "FDA-compliant." Venable specifically warns against those terms, and AmSpa reminds practices that the policy is not approval. Avoid treatment claims you can't support, and check your state's advertising rules for compounded drugs. Google and Meta also restrict ads that promote unapproved drugs, so expect paid ads for these services to be limited or rejected.

How to explain it to patients

Patients will have seen headlines saying peptides are "legal now." A short script helps your front desk and providers say the same thing:

"A federal health agency has said it won't take action against licensed pharmacies that compound these specific peptides under strict conditions while the FDA finishes its review. They're still compounded drugs, not FDA-approved medications, and the policy is temporary. If it's right for you, your provider will prescribe it just for you, from a pharmacy we've vetted."

Where Prospyr fits

The policy turns a peptide service into a documentation workflow: a patient-specific order, a signed consent, a chart that shows the evaluation and the exact product, and a record of any reaction. Prospyr keeps those in one patient record. E-prescribing sends the order from the chart to the patient's pharmacy through DoseSpot, digital intake collects updated consent forms before the visit, and smart note templates in charting can be set up so every peptide note records the product, salt form, route and course dates. If you're rebuilding a peptide program and want to see that workflow, book a Prospyr demo. Providers new to peptides can compare peptide therapy training programs.

Frequently asked questions

Not in the sense of being approved. Under the HHS policy, the federal government does not intend to take enforcement action against 503A compounding of BPC-157 acetate for subcutaneous, intramuscular, oral or topical use when all ten conditions are met. It is still an unapproved compounded drug, it is not on the 503A bulks list, and state law still applies.

Are the six peptides FDA-approved?

No. The Federal Register notice says compounded drugs are not FDA-approved and that FDA does not review their safety, effectiveness or quality before they're marketed.

Can my med spa keep these peptides in stock?

Not from a 503A pharmacy under this policy. It keeps the 503A requirement of a prescription for an identified patient, and it does not cover 503B outsourcing facilities, which are the usual source of office stock.

Does the policy cover peptide blends?

No. Each compounded product must contain a single active ingredient from the HHS list.

How long will the policy last?

There is no end date. Discretion continues until each peptide is addressed in a final rule on the 503A bulks list, and HHS can revisit it sooner if a safety signal or quality issue arises.

Can we advertise peptide therapy?

You can describe the service, but don't call the peptides FDA-approved, legalized or FDA-compliant, and check your state's rules on advertising compounded drugs. Expect Meta and Google to restrict ads that promote unapproved drugs.

Sources

Editorial scope

This article is based on the Federal Register notice and published summaries of the HHS policy, checked November 17, 2026, with AI-assisted research. The conditions table paraphrases the policy as summarized by Venable LLP; read the HHS document itself before relying on any single condition. Policies on compounded peptides are changing quickly, so check for updates before you act. Read our methodology or report a correction.

Run your practice on one system